Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.

more >
Materials for 24 May 2017 Annual Meeting
  • Agenda & Resolutions FR | ENG
  • Board report on extraordinary resolutions FR | ENG
  • CV of proposed board member ENG
  • Lettre aux actionnaires FR
  • Comptes annuels FR
  • IFRS consolidated financial statements FR | ENG
  • 2016 Annual Report ENG
  • Auditors Report on IFRS Accounts ENG
  • Auditors report on AAA S.A. accounts FR
  • Auditors report on AAA S.A. related party transactions FR
Latest Newsmore >
Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter First Quarter 2017 Highlights: Advanced preparations for resubmission of lutetium Lu 177 dotatate (Lutathera®) New Drug Application to FDA Results of Phase 3 NETTER-1 study of investigational drug lutetium Lu 177 dotatate (Lutathera®) published in The New England Journal of Medicine Enhanced supply chain for lutetium 177-labeled product... 
Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer
SAINT-GENIS-POUILLY, France and OXFORD, UK, May 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine, and Blue Earth Diagnostics Ltd., a molecular imaging diagnostics company, today announced that they have entered into a non-exclusive manufacturing agreement and an exclusive distribution agreement for the supply of Blue Earth Diagnostics’ PET imaging product Axumin™ (fluciclovine (18F)) in France, Ge... 
Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors
SAINT-GENIS-POUILLY, France, May 25, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Christine Mikail, J.D. has joined the Company’s board of directors as an independent non-executive director. “Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry,” stated Stefano Buono, Chief Executi... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources